Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies [Corrigendum]
Barabássy Á, Sebe B, Acsai K, et al. Neuropsychiatr Dis Treat. 2021;17:957–970. The authors have advised that there are errors in the first row of Table 5 on page 963. Cariprazine 4.5 mg column, the value “1 (0.0)” should ...
Guardado en:
| Autores principales: | , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/cf336b8f9cd74908af6e74a46e31c7e7 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Barabássy Á, Sebe B, Acsai K, et al. Neuropsychiatr Dis Treat. 2021;17:957–970.
The authors have advised that there are errors in the first row of Table 5 on page 963.
Cariprazine 4.5 mg column, the value “1 (0.0)” should read “1 (0.2)”. Cariprazine 6 mg column, “2 (0.0)” should read “2 (0.3)”. Total 1.5-6 mg/d column, “0” should read “3 (0.1)”.
The authors apologize for these errors.
Read the original article |
|---|